【24h】

Improving method capability of a drug substance HPLC assay.

机译:改进药物HPLC测定的方法能力。

获取原文
获取原文并翻译 | 示例
           

摘要

The assay of a drug substance (DS) is one of the tests required to confirm the active pharmaceutical ingredient (API) quality at release. In the past, usually volumetric titration methods were performed, that were precise, but often non-specific. Nowadays specific chromatographic assay procedures are preferred. However, high performance liquid chromatographic (HPLC) methods, the way they are usually executed, tend to be less precise and have a larger total method variation compared to titration methods. The capabilities of fully validated titration and HPLC assay methods were determined and compared. It was studied which factors had the largest effects on the capability of chromatographic HPLC methods in order to improve their precision and precision-to-tolerance ratio. This was done using multiple Gage R&R (repeatability & reproducibility) studies and an experimental design approach. The investigations showed that it was feasible to define an HPLC method with a similar capability as the titration method. The most important factor determining the precision was demonstrated to be higher sample and reference material weights. When low weights are to be used, increasing the number of sample preparations and the number of reference solutions may enhance the method capability.
机译:原料药(DS)的测定是确认释放时的活性药物成分(API)质量所需的测试之一。过去,通常使用体积滴定法,这种方法很精确,但通常是非特异性的。如今,优选特定的色谱分析程序。但是,与滴定方法相比,高性能液相色谱(HPLC)方法通常采用的方法往往精度较低,并且总的方法变化较大。确定并比较了完全验证的滴定和HPLC分析方法的功能。研究了哪些因素对色谱HPLC方法性能的影响最大,以提高其精密度和精密度/公差比。这是使用多个Gage R&R(重复性和可再现性)研究和实验设计方法完成的。研究表明,定义一种具有与滴定法相似功能的HPLC方法是可行的。决定精度的最重要因素是较高的样品和标准物质重量。当使用低重量时,增加样品制备的数量和参考溶液的数量可以增强方法的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号